Ocular Therapeutix, Inc. (OCUL)

NASDAQ: OCUL · IEX Real-Time Price · USD

5.22

-0.64 (-10.92%)

At close: Apr 19, 2024, 4:00 PM

5.24

+0.02 (0.38%)

After-hours: Apr 19, 2024, 5:43 PM EDT

Ocular Therapeutix Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Net Income	-80.74	-71.04	-6.55	-155.64	-86.37	-59.98	-63.39	-44.7	-39.75	-28.66	Upgrade
Depreciation & Amortization	2.98	2.11	2.42	2.77	2.53	2.29	1.63	0.88	0.75	0.55	Upgrade
Share-Based Compensation	17.83	16.96	14.98	7.53	8.76	7.48	7.32	5.96	4.64	2.64	Upgrade
Other Operating Activities	-10.31	-7.64	-76.4	91.78	-2.5	0.98	3.97	3.87	0.61	4.96	Upgrade
Operating Cash Flow	-70.23	-59.6	-65.55	-53.55	-77.58	-49.23	-50.47	-34	-33.74	-20.5	Upgrade
Capital Expenditures	-6.09	-3.72	-1.19	-0.84	-2.24	-1.89	-8.25	-1.92	-1.77	-1.26	Upgrade
Change in Investments	0	0	0	0	0	0	35.2	38.99	-36.86	-37.33	Upgrade
Other Investing Activities	-	-	-	-	-	-	-	-	0.06	-	Upgrade
Investing Cash Flow	-6.09	-3.72	-1.19	-0.84	-2.24	-1.89	26.95	37.07	-38.57	-38.59	Upgrade
Share Issuance / Repurchase	118.66	1.45	3.57	228.01	38.07	62.27	30.2	1.1	66.07	69.62	Upgrade
Debt Issued / Paid	51.17	0	-0.45	0	37.28	6.38	2.4	0	0.4	-2.27	Upgrade
Other Financing Activities	-	-	-0.28	-	-	-	-0.59	-0.52	-0.76	11.63	Upgrade
Financing Cash Flow	169.83	1.45	2.85	228.01	75.34	68.64	32.01	0.59	65.7	78.97	Upgrade
Net Cash Flow	93.51	-61.86	-63.89	173.62	-4.48	17.52	8.49	3.65	-6.61	19.89	Upgrade
Free Cash Flow	-76.32	-63.32	-66.74	-54.4	-79.82	-51.12	-58.72	-35.92	-35.51	-21.76	Upgrade
Free Cash Flow Margin	-130.59%	-122.96%	-153.36%	-312.56%	-1888.24%	-2568.64%	-3053.56%	-1903.44%	-2029.37%	-2818.13%	Upgrade
Free Cash Flow Per Share	-0.96	-0.82	-0.87	-0.90	-1.76	-1.34	-2.04	-1.45	-1.53	-2.04	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).